Total submissions: 5
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Invitae | RCV000456750 | SCV000541552 | likely benign | Brugada syndrome 8 | 2023-11-20 | criteria provided, single submitter | clinical testing | |
Athena Diagnostics Inc | RCV000711885 | SCV000842296 | uncertain significance | not provided | 2017-12-21 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV003168728 | SCV003912956 | uncertain significance | Cardiovascular phenotype | 2023-02-07 | criteria provided, single submitter | clinical testing | The p.P846L variant (also known as c.2537C>T), located in coding exon 8 of the HCN4 gene, results from a C to T substitution at nucleotide position 2537. The proline at codon 846 is replaced by leucine, an amino acid with similar properties. This variant was detected in a cardiomyopathy/arrhythmia genetic testing cohort; however, clinical details were limited, and additional cardiac variants were detected in some cases (van Lint FHM et al. Neth Heart J, 2019 Jun;27:304-309). This amino acid position is well conserved in available vertebrate species. In addition, this alteration is predicted to be tolerated by in silico analysis. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear. |
Clinical Genetics, |
RCV000711885 | SCV001920984 | uncertain significance | not provided | no assertion criteria provided | clinical testing | ||
Diagnostic Laboratory, |
RCV000711885 | SCV001963557 | uncertain significance | not provided | no assertion criteria provided | clinical testing |